Novel Approaches for Risk Stratifying Newly Diagnosed Localized Prostate Cancer
By Phouc T. Tran, MD, PhD - Last Updated: February 24, 2023Phouc T. Tran, MD, PhD, University of Maryland Radiation Oncology, highlights the challenges of accurate and effective risk stratification for newly diagnosed localized prostate cancer and summarizes novel risk stratification tools, such as gene expression and digital pathology.
Post Tags:ASCO GU 2023-Prostate Cancer
Related Posts
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.